RhyGaze raised $86M in a Series A round led by GV to further develop a novel gene therapy for vision restoration.
RhyGaze raised $86M in a Series A round led by GV to further develop a novel gene therapy for vision restoration.
01/10/25, 1:36 PM
Location
baselMoney raised
$86 million
Industry
biotechnology
health care
Round Type
series a
Investors
Novartis Venture Fund, Bio Generation Ventures, F Prime Capital, Arch Venture Partners, Gv
RhyGaze secured a Series A financing of USD 86 million to advance its lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. The funding will support pharmacology and toxicology testing, observational studies, and a first-in-human clinical trial.